BioSpace News Archive

RetinAI Medical AG announces a multi-year collaboration with Novartis Pharma AG under which RetinAI’s IT solutions and artificial intelligence tools shall be employed to support multiple projects in ophthalmology and digital health.

Orange County moms-to-be can now experience labor, delivery and the first precious moments with their newborns all in the same suite

WASHINGTON, Dec. 9, 2020 /PRNewswire/ -- The Pharmaceutical Research and Manufacturers of America (PhRMA) is pleased to announce that David Ricks, chairman and CEO of Eli Lilly and Company, has assumed the role of chairman of the PhRMA board of directors.

Verantos today announced it has received a grant award from the U.S. Food and Drug Administration (FDA) to implement a multi-year advanced real-world evidence (RWE) study. The program, “Trans

the American Diabetes Association® released the 2021 Standards of Medical Care in Diabetes. The 2021 Standards of Care is now live online in Diabetes Care.

Lantheus Holdings, Inc. and Progenics Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted the New Drug Application for PyLTM, a prostate specific membrane antigen -targeted positron emission tomography imaging agent for prostate cancer.

Transaction provides a complementary fit with Sartorius Stedim Biotech’s separation portfolio, adding innovative crossflow filtration units for easy-to-use bioprocessing devices Technology is especially suited to gene and cell therapy applications, vaccine production and intensified bioprocessing

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announced that David J. Mazzo, PhD, the Company’s President and CEO, will be presenting at the 13th annual LD Micro Main Event investor conference on Monday, December 14, 2020 at 10:20 AM Eastern Time.

Ultragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to UX701 for the treatment of Wilson disease, a larger rare metabolic disease that affects more than 50,000 people in the developed world.

AngioDynamics, Inc., a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, announced that it will report financial results for the second quarter of fiscal year 2021 before the market open on Thursday, January 7, 2021.